SNY vs. WST: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at SNY and WST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
SNY trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, WST is a standard domestic listing.
| Symbol | SNY | WST |
|---|---|---|
| Company Name | Sanofi | West Pharmaceutical Services, Inc. |
| Country | France | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 127.74 billion USD | 19.04 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 1, 2002 | March 17, 1980 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of SNY and WST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | SNY | WST |
|---|---|---|
| 5-Day Price Return | 0.94% | -5.12% |
| 13-Week Price Return | 3.93% | 6.16% |
| 26-Week Price Return | -3.88% | 21.07% |
| 52-Week Price Return | -1.08% | -24.02% |
| Month-to-Date Return | 2.61% | -7.34% |
| Year-to-Date Return | -4.11% | -20.21% |
| 10-Day Avg. Volume | 1.47M | 0.71M |
| 3-Month Avg. Volume | 1.85M | 0.70M |
| 3-Month Volatility | 28.76% | 34.12% |
| Beta | 1.08 | 1.17 |
Profitability
Return on Equity (TTM)
SNY
18.76%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
SNY’s Return on Equity of 18.76% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
WST
17.33%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, WST’s Return on Equity of 17.33% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
SNY
20.66%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 20.66% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
WST
16.29%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
WST’s Net Profit Margin of 16.29% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
SNY
20.74%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
SNY’s Operating Profit Margin of 20.74% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
WST
19.48%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
WST’s Operating Profit Margin of 19.48% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | SNY | WST |
|---|---|---|
| Return on Equity (TTM) | 18.76% | 17.33% |
| Return on Assets (TTM) | 10.65% | 12.84% |
| Net Profit Margin (TTM) | 20.66% | 16.29% |
| Operating Profit Margin (TTM) | 20.74% | 19.48% |
| Gross Profit Margin (TTM) | 72.29% | 35.58% |
Financial Strength
Current Ratio (MRQ)
SNY
1.06
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
SNY’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
WST
2.87
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
WST’s Current Ratio of 2.87 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
SNY
0.30
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.30 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
WST
0.07
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
Falling into the lower quartile for the Life Sciences Tools & Services industry, WST’s Debt-to-Equity Ratio of 0.07 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
WST
130.12
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 130.12, WST demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | SNY | WST |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 2.87 |
| Quick Ratio (MRQ) | 0.30 | 2.18 |
| Debt-to-Equity Ratio (MRQ) | 0.30 | 0.07 |
| Interest Coverage Ratio (TTM) | 22.06 | 130.12 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
SNY
4.40%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.40%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
WST
0.31%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Yield of 0.31% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
WST
12.34%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Payout Ratio of 12.34% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | SNY | WST |
|---|---|---|
| Dividend Yield (TTM) | 4.40% | 0.31% |
| Dividend Payout Ratio (TTM) | 52.56% | 12.34% |
Valuation
Price-to-Earnings Ratio (TTM)
SNY
7.90
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 7.90 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
WST
40.29
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
WST’s P/E Ratio of 40.29 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
SNY
1.63
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, SNY’s P/S Ratio of 1.63 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
WST
6.56
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
WST’s P/S Ratio of 6.56 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
SNY
1.32
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
SNY’s P/B Ratio of 1.32 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
WST
6.18
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
WST’s P/B Ratio of 6.18 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | SNY | WST |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 7.90 | 40.29 |
| Price-to-Sales Ratio (TTM) | 1.63 | 6.56 |
| Price-to-Book Ratio (MRQ) | 1.32 | 6.18 |
| Price-to-Free Cash Flow Ratio (TTM) | 10.85 | 52.25 |